STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Millennium/Englander Disclose 1,426,893-Share Position in ANAB

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report beneficial ownership of 1,426,893 shares of AnaptysBio, Inc. (ANAB), representing 5.1% of the outstanding common stock. The Schedule 13G discloses shared voting and dispositive power over these shares with no sole voting or dispositive power reported. The filing indicates the securities are held by entities subject to voting control and investment discretion by Millennium and related managers.

The filing includes a Joint Filing Agreement dated September 22, 2025, and certifications that the holdings were not acquired to change or influence control of the issuer. Addresses for the reporting persons and CUSIP 032724106 are provided.

Positive

  • Transparent disclosure of a 5.1% stake by established institutional investors
  • Joint Filing Agreement and signatures confirming coordinated reporting and compliance

Negative

  • Shared voting power indicates influence is dispersed rather than centralized, limiting clarity on decision-making authority
  • No detail in the filing about which specific affiliated entities hold the shares or trading intentions

Insights

TL;DR: A reported passive 5.1% stake by Millennium/Englander signals a meaningful institutional position without an explicit control intent.

The Schedule 13G shows a disclosed aggregate position of 1,426,893 shares, equal to 5.1% of ANAB, reported as shared voting and dispositive power across Millennium entities and Israel A. Englander. Filing under Schedule 13G typically indicates an investor claims passive intent rather than an activist or control purpose. The disclosure and joint filing agreement provide transparency on ownership structure and reporting responsibility but do not convey changes in corporate governance or new strategic plans. For investors, the development documents a material institutional holder above the 5% reporting threshold, which can affect liquidity and potential block trading dynamics.

TL;DR: Ownership crossing the 5% threshold requires disclosure; no indication of control or solicitation is stated.

The filing identifies shared voting and dispositive power rather than sole control, and includes the required certification that the stake was not acquired to influence control. The inclusion of a Joint Filing Agreement and signatures dated September 22, 2025, formalize the coordinated reporting among the parties. Absent additional arrangements or amendments, this Schedule 13G signals compliance with disclosure rules while asserting a non-control posture. Market participants should note the precise 5.1% figure as the crossing point that triggers visibility but not necessarily governance influence.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Millennium Management LLC
Signature:/s/ Gil Raviv
Name/Title:Gil Raviv, Global General Counsel
Date:09/22/2025
Millennium Group Management LLC
Signature:/s/ Gil Raviv
Name/Title:Gil Raviv, Global General Counsel
Date:09/22/2025
Israel A. Englander
Signature:/s/ Israel A. Englander
Name/Title:Israel A. Englander
Date:09/22/2025
Exhibit Information

Exhibit I: Joint Filing Agreement, dated as of September 22, 2025, by and among Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.

FAQ

What stake in ANAB did Millennium report?

The filing reports beneficial ownership of 1,426,893 shares, representing 5.1% of AnaptysBio common stock.

Who filed the Schedule 13G for ANAB?

The Schedule 13G was filed by Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.

Does the filing indicate an intent to control AnaptysBio?

No. The filers certified the securities were not acquired to change or influence control and filed on Schedule 13G, which indicates passive intent under the rules.

What voting and dispositive powers are reported?

The filers report 0 sole voting power, 1,426,893 shared voting power, 0 sole dispositive power, and 1,426,893 shared dispositive power.

When was the Joint Filing Agreement executed?

Exhibit I is a Joint Filing Agreement dated September 22, 2025.
Anaptysbio Inc

NASDAQ:ANAB

ANAB Rankings

ANAB Latest News

ANAB Latest SEC Filings

ANAB Stock Data

1.23B
26.07M
5.82%
124.31%
34.67%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN DIEGO